Literature DB >> 25008067

11q23 abnormalities in adult Chinese patients with hematological malignancies.

Xiaoli Zhao1, Shuang Li, Nianyi Li, Rong Fan, Guowei Lin, Xiaoqin Wang.   

Abstract

The mixed lineage leukemia (MLL) gene on chromosome region 11q23 is frequently involved in chromosomal translocations associated with various human hematologic malignant neoplasms. The aim of this study was to investigate the profile of 11q23 abnormalities in adult Chinese patients with hematological malignancies. In this study, 11q23 abnormalities were detected by cytogenetic and fluorescence in situ hybridization (FISH) approaches in 77 out of a total of 2,404 adult Chinese patients with leukemia, lymphoma, and myelodysplastic syndrome (MDS). 11q23 abnormalities were found in 5.31 % of the acute myeloid leukemia (AML) cases, 5.71 % of the acute lymphoid leukemia (ALL) cases, 2.94 % of lymphoma cases, and 1.24 % of MDS cases. Of the patients with 11q23 abnormalities, 59.74 % showed rearrangement or deletion of the MLL gene by FISH; a novel 11q23 rearrangement, der(6)t(6;11)(q23;q23), was discovered in one case. Our data showed that t(11;19)(q23;p13.1) was the most frequent translocation in AML patients and t(4;11)(q21;q23) was the most frequent translocation in ALL patients. FLT-ITD mutations were detected in three out of 33 AML patients with 11q23 abnormalities (9.09 %). The Kaplan-Meier survival analysis further showed that the 11q23 aberration was a poor prognostic factor for AML. The median survival times in the 11q23 aberration subgroup, the normal karyotype subgroup, and the subgroup with other abnormalities were 7.4, 11.3, and 16.8 months, respectively (P = 0.0464). Our study found one novel 11q23 rearrangement, der(6)t(6;11)(q23;q23), and demonstrated the profile of 11q23 abnormalities in adult Chinese patients with hematological malignancies.

Entities:  

Mesh:

Year:  2014        PMID: 25008067     DOI: 10.1007/s12032-014-0115-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  39 in total

Review 1.  The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia.

Authors:  Marc De Braekeleer; Frédéric Morel; Marie-Josée Le Bris; Angèle Herry; Nathalie Douet-Guilbert
Journal:  Anticancer Res       Date:  2005 May-Jun       Impact factor: 2.480

2.  MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.

Authors:  Qian-Fei Wang; George Wu; Shuangli Mi; Fuhong He; Jun Wu; Jingfang Dong; Roger T Luo; Ryan Mattison; Joseph J Kaberlein; Shyam Prabhakar; Hongkai Ji; Michael J Thirman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

3.  Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.

Authors:  Eva A Coenen; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

4.  Cytogenetic profile of a large cohort of Tunisian de novo acute myeloid leukemia.

Authors:  Abir Gmidène; Hlima Sennana; Ines Wahchi; Yosra Ben Youssef; Ramzi Jeddi; Moez Elloumi; Ali Saad
Journal:  Hematology       Date:  2012-01       Impact factor: 2.269

5.  Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group.

Authors:  W Wang; X-Q Wang; X-P Xu; G-W Lin
Journal:  J Int Med Res       Date:  2010 Mar-Apr       Impact factor: 1.671

Review 6.  Molecular pathology of mixed-lineage leukemia.

Authors:  Christian Bach; Robert K Slany
Journal:  Future Oncol       Date:  2009-10       Impact factor: 3.404

Review 7.  Geography, ethnicity and "roots" in chronic lymphocytic leukemia.

Authors:  Rosa Ruchlemer; Aaron Polliack
Journal:  Leuk Lymphoma       Date:  2012-12-10

8.  Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.

Authors:  K M Bernot; R F Siebenaler; S P Whitman; N A Zorko; G G Marcucci; R Santhanam; E H Ahmed; M Ngangana; K K McConnell; J S Nemer; D L Brook; S K Kulp; C S Chen; D Frankhouser; P Yan; R Bundschuh; X Zhang; A M Dorrance; K E Dickerson; D Jarjoura; W Blum; G Marcucci; M A Caligiuri
Journal:  Leukemia       Date:  2013-05-10       Impact factor: 11.528

Review 9.  Recent progress toward epigenetic therapies: the example of mixed lineage leukemia.

Authors:  Tobias Neff; Scott A Armstrong
Journal:  Blood       Date:  2013-05-06       Impact factor: 22.113

10.  The MLL recombinome of acute leukemias in 2013.

Authors:  C Meyer; J Hofmann; T Burmeister; D Gröger; T S Park; M Emerenciano; M Pombo de Oliveira; A Renneville; P Villarese; E Macintyre; H Cavé; E Clappier; K Mass-Malo; J Zuna; J Trka; E De Braekeleer; M De Braekeleer; S H Oh; G Tsaur; L Fechina; V H J van der Velden; J J M van Dongen; E Delabesse; R Binato; M L M Silva; A Kustanovich; O Aleinikova; M H Harris; T Lund-Aho; V Juvonen; O Heidenreich; J Vormoor; W W L Choi; M Jarosova; A Kolenova; C Bueno; P Menendez; S Wehner; C Eckert; P Talmant; S Tondeur; E Lippert; E Launay; C Henry; P Ballerini; H Lapillone; M B Callanan; J M Cayuela; C Herbaux; G Cazzaniga; P M Kakadiya; S Bohlander; M Ahlmann; J R Choi; P Gameiro; D S Lee; J Krauter; P Cornillet-Lefebvre; G Te Kronnie; B W Schäfer; S Kubetzko; C N Alonso; U zur Stadt; R Sutton; N C Venn; S Izraeli; L Trakhtenbrot; H O Madsen; P Archer; J Hancock; N Cerveira; M R Teixeira; L Lo Nigro; A Möricke; M Stanulla; M Schrappe; L Sedék; T Szczepański; C M Zwaan; E A Coenen; M M van den Heuvel-Eibrink; S Strehl; M Dworzak; R Panzer-Grümayer; T Dingermann; T Klingebiel; R Marschalek
Journal:  Leukemia       Date:  2013-04-30       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.